Irbesartan Bgr

Irbesartan, the active ingredient in Irbesartan Bgr, is an angiotensin II receptor blocker presented as a tablet for oral use. It is employed to lower high blood pressure and to protect kidney function in patients with diabetic nephropathy, particularly in the European Union market where it is approved.

GNH USA supplies Irbesartan Bgr as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan acts on the renin‑angiotensin‑aldosterone system to manage conditions related to elevated blood pressure and kidney disease. - Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications. - Diabetic nephropathy: slows progression of kidney damage in patients with type 2 diabetes. - Chronic kidney disease with hypertension: improves blood pressure control and reduces proteinuria, supporting renal preservation.

Irbesartan is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity, often transient. - Fatigue: feeling unusually tired or weak. - Nausea: upset stomach or urge to vomit. - Hyperkalemia: elevated blood potassium levels, usually mild.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat that may compromise breathing. - Acute renal failure: sudden decline in kidney function, indicated by rising creatinine. - Severe hyperkalemia: potassium levels markedly high, risking cardiac arrhythmia. - Hepatic injury: abnormal liver enzymes or jaundice. - Hypotension: excessive drop in blood pressure causing faintness.

Before initiating therapy, clinicians should consider several safety measures. - Monitor blood pressure: ensure target levels are achieved without excessive drop. - Assess renal function: check serum creatinine and eGFR periodically. - Check serum potassium: especially when combined with potassium‑sparing agents. - Use caution in hepatic impairment: dose adjustments may be required. - Pregnancy and lactation: avoid use unless benefits outweigh risks, as safety data are limited. - Store at room temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase risk of renal impairment and hyperkalemia. - Dual blockade with ACE inhibitors or other ARBs: may cause excessive hypotension, renal dysfunction, and high potassium. - Potassium‑sparing diuretics (e.g., spironolactone): heightens risk of severe hyperkalemia.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen): can reduce antihypertensive effect and impair renal function. - Lithium: may increase lithium concentrations, risking toxicity. - Diuretics (thiazides): may enhance antihypertensive effect, requiring dose adjustment. - CYP2C9 inhibitors (e.g., fluconazole): can raise irbesartan plasma levels modestly.